Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 4/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.46 |
| ▸ | TARBP2 | Q15633 | 5/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | ELANE | P08246 | 1/20 | 0.42 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.42 |
| ▸ | PDCD4 | Q53EL6 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.41 |
| ▸ | APLNR | P35414 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3185603 | 0.88 | HDAC1 (0.47) | HDAC1HDAC8HDAC6TARBP2CYP1A2 | |
| SCHEMBL20361433 | 0.86 | TARBP2 (0.60) | HDAC1HDAC8HDAC6TARBP2CYP1A2 | |
| SCHEMBL26315180 | 0.86 | HDAC1 (0.61) | HDAC1HDAC8HDAC6TARBP2CYP1A2 | |
| SCHEMBL3070077 | 0.85 | PDE4B (0.53) | HDAC1HDAC8HDAC6TARBP2CYP1A2 | |
| SCHEMBL24339961 | 0.84 | ELANE (0.53) | HDAC1HDAC8HDAC6TARBP2CYP1A2 | |
| SCHEMBL2817924 | 0.84 | HDAC1 (0.58) | HDAC1HDAC8HDAC6TARBP2CYP1A2 | |
| SCHEMBL2792417 | 0.83 | ALDH1A1 (0.59) | HDAC1HDAC8HDAC6TARBP2CYP1A2 | |
| SCHEMBL17055727 | 0.83 | HDAC1 (0.64) | HDAC1HDAC8HDAC6TARBP2PDCD4 | |
| SCHEMBL3081837 | 0.83 | HDAC1 (0.45) | HDAC1HDAC8HDAC6TARBP2CYP1A2 | |
| SCHEMBL12571352 | 0.82 | CDC7 (0.51) | HDAC1HDAC8HDAC6TARBP2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7803825-B2 | Aminoalkylazole derivatives as histamine-3 antagonists | WYETH LLC (US) | 2010-09-28 | — | — | US | disclosed |
| US-7803825-B2 | Aminoalkylazole derivatives as histamine-3 antagonists | WYETH LLC (US) | 2010-09-28 | — | — | US | disclosed |
| US-7803825-B2 | Aminoalkylazole derivatives as histamine-3 antagonists | WYETH LLC (US) | 2010-09-28 | — | — | US | disclosed |
| EP-2170875-A1 | AMINOALKYLAZOLE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | Wyeth LLC (US) | 2010-04-07 | — | — | EP | disclosed |
| WO-2010009029-A2 | METHODS FOR THE PREPARATION OF AZOLE COMPOUNDS | WYETH (US) | 2010-01-21 | — | — | WO | disclosed |
| WO-2010009029-A2 | METHODS FOR THE PREPARATION OF AZOLE COMPOUNDS | WYETH (US) | 2010-01-21 | — | — | WO | disclosed |
| US-20100016609-A1 | METHODS FOR THE PREPARATION OF AZOLE COMPOUNDS | WYETH (US) | 2010-01-21 | — | — | US | disclosed |
| US-20100016609-A1 | METHODS FOR THE PREPARATION OF AZOLE COMPOUNDS | WYETH (US) | 2010-01-21 | — | — | US | disclosed |
| US-20100016609-A1 | METHODS FOR THE PREPARATION OF AZOLE COMPOUNDS | WYETH (US) | 2010-01-21 | — | — | US | disclosed |
| WO-2009012252-A1 | AMINOALKYLAZOLE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2009-01-22 | — | — | WO | disclosed |
| US-20090023707-A1 | AMINOALKYLAZOLE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2009-01-22 | — | — | US | disclosed |
| US-20090023707-A1 | AMINOALKYLAZOLE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2009-01-22 | — | — | US | disclosed |
| US-20090023707-A1 | AMINOALKYLAZOLE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2009-01-22 | — | — | US | disclosed |
| WO-2009012252-A1 | AMINOALKYLAZOLE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023707-A1 | AMINOALKYLAZOLE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | HRH4, HRH3, HRH2 | HDAC1 1951/4885HDAC8 2412/4885HDAC6 1042/4885 |
| US-20100016609-A1 | METHODS FOR THE PREPARATION OF AZOLE COMPOUNDS | CYP3A5, CYP3A7, CYP11B1 | HDAC1 3075/4885HDAC8 2749/4885HDAC6 2827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.